Unexpected vaginal bleeding and COVID-19 vaccination in nonmenstruating women.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
22 09 2023
Historique:
medline: 25 9 2023
pubmed: 22 9 2023
entrez: 22 9 2023
Statut: ppublish

Résumé

The association between coronavirus disease 2019 (COVID-19) vaccination and vaginal bleeding among nonmenstruating women is not well studied. The Norwegian Institute of Public Health followed several cohorts throughout the pandemic and early performed a systematic data collection of self-reported unexpected vaginal bleeding in nonmenstruating women. Among 7725 postmenopausal women, 7148 perimenopausal women, and 7052 premenopausal women, 3.3, 14.1, and 13.1% experienced unexpected vaginal bleeding during a period of 8 to 9 months, respectively. In postmenopausal women, the risk of unexpected vaginal bleeding (i.e., postmenopausal bleeding) in the 4 weeks after COVID-19 vaccination was increased two- to threefold, compared to a prevaccination period. The corresponding risk of unexpected vaginal bleeding after vaccination was increased three- to fivefold in both nonmenstruating peri- and premenopausal women. In the premenopausal women, Spikevax was associated with at 32% increased risk as compared to Comirnaty. Our results must be confirmed in future studies.

Identifiants

pubmed: 37738335
doi: 10.1126/sciadv.adg1391
pmc: PMC10516485
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eadg1391

Références

Science. 2022 Nov 18;378(6621):704-706
pubmed: 36395209
Mod Pathol. 2000 Mar;13(3):285-94
pubmed: 10757339
BJOG. 2023 Jun;130(7):803-812
pubmed: 37035899
Lancet Healthy Longev. 2023 May;4(5):e188-e199
pubmed: 37148891
Obstet Gynecol. 2018 May;131(5):e124-e129
pubmed: 29683909
Vaccine. 2023 Jan 9;41(2):614-620
pubmed: 36517325
Vacunas. 2022 Sep-Dec;23:S77-S87
pubmed: 35873308
Int J Epidemiol. 2016 Apr;45(2):382-8
pubmed: 27063603
JAMA Cardiol. 2022 Jun 1;7(6):600-612
pubmed: 35442390
J Obstet Gynaecol Res. 2022 Nov;48(11):2903-2910
pubmed: 36319205
JAMA Intern Med. 2018 Sep 1;178(9):1210-1222
pubmed: 30083701
BMJ. 2023 May 3;381:e074778
pubmed: 37137493
BMJ. 2023 May 17;381:1122
pubmed: 37197776
Lancet Digit Health. 2022 Sep;4(9):e667-e675
pubmed: 35961858
Am J Obstet Gynecol. 2017 May;216(5):443-450
pubmed: 27988268
J Clin Endocrinol Metab. 2012 Apr;97(4):1159-68
pubmed: 22344196
Br J Obstet Gynaecol. 1995 Feb;102(2):133-6
pubmed: 7756204
Eur J Epidemiol. 2019 Oct;34(10):927-938
pubmed: 31451995
Acta Obstet Gynecol Scand. 2004 Feb;83(2):203-7
pubmed: 14756741
Paediatr Perinat Epidemiol. 2009 Nov;23(6):597-608
pubmed: 19840297
Climacteric. 2020 Dec;23(6):550-558
pubmed: 32893694
JAMA Netw Open. 2021 Dec 1;4(12):e2140364
pubmed: 34935921
Obstet Gynecol. 2010 Aug;116(2 Pt 1):305-310
pubmed: 20664389
J Clin Pathol. 2001 Jun;54(6):435-40
pubmed: 11376015
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
NPJ Digit Med. 2022 Nov 2;5(1):165
pubmed: 36323769
Vaccine. 2023 Aug 14;41(36):5271-5282
pubmed: 37451876
Maturitas. 2010 Sep;67(1):60-6
pubmed: 20494530
BMC Womens Health. 2022 Oct 5;22(1):403
pubmed: 36195902
Sci Adv. 2022 Jul 15;8(28):eabm7201
pubmed: 35857495
Am J Epidemiol. 2012 Mar 15;175(6):536-45
pubmed: 22350580
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Biol Reprod. 2021 Feb 11;104(2):336-343
pubmed: 33205194
Am J Obstet Gynecol. 2022 Dec;227(6):907-908
pubmed: 35835262
Am J Obstet Gynecol. 2022 Jul 13;:
pubmed: 35841938

Auteurs

Kristine Blix (K)

Department of Method Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway.

Ida Laake (I)

Department of Method Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway.

Lene Juvet (L)

Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway.

Anna Hayman Robertson (AH)

Department of Method Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway.

Ida Henriette Caspersen (IH)

Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.

Siri Mjaaland (S)

Department of Method Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway.

Siri N Skodvin (SN)

Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.

Per Magnus (P)

Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.

Berit Feiring (B)

Department of Method Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway.

Lill Trogstad (L)

Department of Method Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH